Lokien van Nunen
Quick facts
Phase 3 pipeline
- Regadenoson central -central · Cardiovascular
Regadenoson central acts as an adenosine A2A receptor agonist, increasing coronary blood flow. - Regadenoson central - peripheral · Cardiovascular
Regadenoson central - peripheral acts as an adenosine A2A receptor agonist. - Regadenoson peripheral - central · Cardiovascular
Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing. - Regadenoson peripheral - peripheral · Cardiovascular
Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: